FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR
FRA:22UA (5/23/2025, 7:00:00 PM)
85.9
-1.1 (-1.26%)
The current stock price of 22UA.DE is 85.9 EUR. In the past month the price decreased by -15.95%. In the past year, price decreased by -2.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 17.75 | 285.16B | ||
AMG.DE | AMGEN INC | 13.04 | 128.74B | ||
GIS.DE | GILEAD SCIENCES INC | 13.71 | 116.78B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.52 | 115.15B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 98.58B | ||
ARGX.BR | ARGENX SE | 108.79 | 31.42B | ||
IDP.DE | BIOGEN INC | 7.87 | 16.14B | ||
1BIIB.MI | BIOGEN INC | 7.52 | 16.03B | ||
1MRNA.MI | MODERNA INC | N/A | 8.79B | ||
0QF.DE | MODERNA INC | N/A | 8.78B | ||
BIO.DE | BIOTEST AG | 66.15 | 1.70B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.68B |
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 6772
Phone: 4949613190840
The current stock price of 22UA.DE is 85.9 EUR. The price decreased by -1.26% in the last trading session.
The exchange symbol of BIONTECH SE-ADR is 22UA and it is listed on the Deutsche Boerse Ag exchange.
22UA.DE stock is listed on the Deutsche Boerse Ag exchange.
27 analysts have analysed 22UA.DE and the average price target is 122.7 EUR. This implies a price increase of 42.84% is expected in the next year compared to the current price of 85.9. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIONTECH SE-ADR (22UA.DE) has a market capitalization of 20.65B EUR. This makes 22UA.DE a Large Cap stock.
BIONTECH SE-ADR (22UA.DE) currently has 6772 employees.
BIONTECH SE-ADR (22UA.DE) has a support level at 83.96 and a resistance level at 89.67. Check the full technical report for a detailed analysis of 22UA.DE support and resistance levels.
The Revenue of BIONTECH SE-ADR (22UA.DE) is expected to decline by -22.85% in the next year. Check the estimates tab for more information on the 22UA.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
22UA.DE does not pay a dividend.
BIONTECH SE-ADR (22UA.DE) will report earnings on 2025-08-04, before the market open.
BIONTECH SE-ADR (22UA.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.2).
ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE. While 22UA.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -3.2. The EPS decreased by -780.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2.95% | ||
ROE | -3.43% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 80% to 22UA.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -92.43% and a revenue growth -22.85% for 22UA.DE